secwatch.observer — SEC 8-K summary
======================================

Issuer:     Savara Inc (SVRA)
CIK:        0001160308
Form:       8-K
Filed at:   2023-07-13T23:59:59+00:00
Accession:  0001193125-23-186640
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Savara prices $80M underwritten offering of common stock and pre-funded warrants at $3.00/share
--------------------------------------------------------------------------------

- Offering of 21M common shares at $3.00/share and 5.67M pre-funded warrants at $2.999/warrant for $80M gross proceeds.
- Expected close July 17, 2023; Jefferies and Piper Sandler are joint book-runners.
- New investors include TCGX, Frazier Life Sciences, Janus Henderson; existing investors Bain, NEA, Adage, Venrock participating.
- Securities offered under effective shelf registration statement (File No. 333-257709).
- Proceeds to fund clinical development and working capital (implied for clinical-stage rare respiratory disease company).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1160308/000119312523186640/0001193125-23-186640-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1160308/000119312523186640/d513110d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-186640

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer